TriGemX Bio announced plans to go public through a SPAC merger, positioning the company to bring late-stage migraine candidate elismetrep into a broader capital runway. The transaction would provide TriGemX with $246 million in cash, combining SPAC reserves and investments from multiple prominent firms. The company previously operated under the Kallyope brand targeting the gut-brain axis, later divesting obesity programs before refocusing on inflammatory neurology. Its shift highlights how SPAC vehicles are being used to re-stage capital access around candidate programs with clearer near-term regulatory and commercial milestones. The move matters for investors and therapeutics developers watching whether public-market liquidity can accelerate late-stage execution for neuroinflammation assets.